Researchers have developed two versions of an experimental monthly injectable semaglutide-loaded hydrogel that shows extended drug release and good tolerance in rats. The formulation aims to address patient adherence issues with current once-weekly or daily dosing regimens for type 2 diabetes or obesity. The hydrogel, injected under the skin, forms a gel disk or microgel suspension that allows for gradual and prolonged drug release over 1 month. Results from rat studies show minimal early release and consistent drug levels over time with no adverse reactions. This promising formulation could improve patient quality of life if found safe and effective in humans.
Source link
The End of Daily Pills?
